Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Anuradha Madan"'
Autor:
Brad H Rovin, Hans-Joachim Anders, Ming-hui Zhao, Ana Malvar, David A Roth, Keiju Hiromura, Jennifer Gilbride, Yulia Green, Anuradha Madan, Angela Jones- Leone, Tania Gonzalez-Rivera
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 3 (2022)
Externí odkaz:
https://doaj.org/article/7f29eaec17ea4f6aa6d1588fc6500122
Autor:
Qinggong Fu, Michelle A Petri, Daniel W Goldman, David A Roth, Selin Cooper Blenkinsopp, Yulia Green, Anuradha Madan, Patricia Juliao
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss 1 (2022)
Objective This retrospective analysis evaluated the prognostic value of renal response status 2 years after biopsy-proven lupus nephritis (LN) for the prediction of long-term renal outcomes.Methods Eligible patients with SLE as per American College o
Externí odkaz:
https://doaj.org/article/3d08e8bdc50f433f92eb50ee85475961
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 8, Iss 8, Pp 1119-1125 (2012)
Objective: This study assessed the immunogenicity, long-term persistence of immune response and safety of a single dose of an A/California/07/2009 H1N1 pandemic influenza vaccine adjuvanted with AS03 (α-tocopherol and squalene based oil-in-water emu
Externí odkaz:
https://doaj.org/article/91a68d0a97004443845f55b6397f7d4f
Autor:
Richard Furie, Brad H. Rovin, Frédéric Houssiau, Gabriel Contreras, Y.K. Onno Teng, Paula Curtis, Yulia Green, Mohamed Okily, Anuradha Madan, David A. Roth
Publikováno v:
Clinical Journal of the American Society of Nephrology, 17(11), 1620-1630. AMER SOC NEPHROLOGY
Background and objectives In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. This 28-week open-label extension of BLISS-LN assessed belimumab's safety and efficacy. Design, setting, participants,
Autor:
Hans-Joachim Anders, Brad H Rovin, Ming-Hui Zhao, Ana Malvar, Keiju Hiromura, Angela Jones- Leone, Tania Gonzalez-Rivera, Jennifer Gilbride, Anuradha Madan, Yulia Green, David A Roth
Publikováno v:
Innate Immunity.
Autor:
Xueqing Yu, Nan Chen, Jun Xue, Chi Chiu Mok, Sang-Cheol Bae, Xiaomei Peng, Wei Chen, Hong Ren, Xiao Li, Kajohnsak Noppakun, Jennifer A. Gilbride, Yulia Green, Beulah Ji, Chang Liu, Anuradha Madan, Mohamed Okily, Chun-Hang Tang, David A. Roth
Publikováno v:
American Journal of Kidney Diseases. 81:294-306.e1
Belimumab improved renal outcomes in patients with active lupus nephritis (LN) in BLISS-LN, leading to its approval in the USA and EU. As data on treatment of East Asian patients with LN are limited, we evaluated the efficacy and safety of belimumab
Autor:
Frédéric Houssiau, Anuradha Madan, Jennifer Gilbride, Y K Onno Teng, Susan Makowiak, Yulia Green, Beulah Ji, Xueqing Yu, Christi Kleoudis, Richard Furie, Brad H. Rovin, David Roth, Ana Malvar, Gabriel Contreras
Publikováno v:
Abstracts.
Autor:
Selin Cooper Blenkinsopp, Qinggong Fu, Yulia Green, Anuradha Madan, Patricia Juliao, Daniel W Goldman, David A Roth, Michelle A Petri
Publikováno v:
Lupus sciencemedicine. 9(1)
ObjectiveThis retrospective analysis evaluated the prognostic value of renal response status 2 years after biopsy-proven lupus nephritis (LN) for the prediction of long-term renal outcomes.MethodsEligible patients with SLE as per American College of
Autor:
M. Okily, Tania Gonzalez-Rivera, Frédéric Houssiau, Y K O Teng, Paula S. Curtis, Angela Jones-Leone, Anuradha Madan, Richard Furie, Brad H. Rovin, Gabriel Contreras, David M. Roth
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Lupus nephritis (LN) is the most common severe manifestation of systemic lupus erythematosus (SLE), occurring in up to 40% of patients (pts) with SLE over their disease course, and resulting in 10–20% of pts progressing to end-s
Autor:
Gabriel Contreras, David M. Roth, Frédéric Houssiau, M. Okily, Paula S. Curtis, Anuradha Madan, Richard Furie, Angela Jones-Leone, Brad H. Rovin
Publikováno v:
Annals of the Rheumatic Diseases. 80:591-592
Background:BLISS-LN (GSK Study BEL114054; NCT01639339), the largest lupus nephritis (LN) study to date, showed that intravenous (IV) belimumab (BEL) + standard therapy (ST) improved outcomes compared with ST alone in patients (pts) with active LN.1Ob